GO:0019964 type II interferon binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0019964 (type II interferon binding) is a molecular function defined as binding to type II interferon, also known as interferon-gamma (IFN-gamma).
• IFN-gamma binding initiates JAK/STAT signaling, which can be modulated by viral proteins to alter T cell adhesion and virus spread.
• Type II interferon binding contributes to host defense by activating the cGAS-STING-IRF3 axis.
• Supersulphides can suppress type I and type II interferon responses by blocking JAK/STAT signaling in macrophages.
• NPM1 selectively regulates type II interferon-inducible genes, linking IFN-gamma binding to gene expression control.
• Dysregulated type II interferon binding is implicated in autoimmune diseases such as pemphigus vulgaris and in inflammatory conditions [5,8].
Description
Type II interferon binding (GO:0019964) is a molecular function that describes the interaction between a protein and interferon-gamma (IFN-gamma), a key cytokine of the type II interferon family. This binding event is the first step in a cascade that leads to the activation of JAK/STAT signaling pathways, which regulate immune responses, cell growth, and differentiation. Researchers study this term to understand how cells sense IFN-gamma and how pathogens or tumors evade or exploit this signaling [1,3]. The importance of type II interferon binding extends to host defense against infections, autoimmune diseases, and cancer immunology [2,5,6]. For example, viral modulation of type II interferon binding can increase T cell adhesion and promote virus spread, highlighting its role in viral pathogenesis. Additionally, activation of the cGAS-STING-IRF3 axis by type I and II interferons contributes to host defense, underscoring the broad impact of IFN-gamma binding. In macrophages, supersulphides suppress type I and type II interferon responses by blocking JAK/STAT signaling, revealing a regulatory mechanism that could be targeted therapeutically. Selective regulation of type II interferon-inducible genes by NPM1/nucleophosmin further demonstrates the complexity of downstream effects following IFN-gamma binding. Clinically, assays for type I and type II interferon activity have been validated for systemic inflammatory diseases, showing the translational relevance of understanding this binding event. Thus, GO:0019964 is a critical molecular function at the interface of immunology and cell biology.
type II interferon binding At A Glance
| GO ID | GO:0019964 |
|---|---|
| GO term | type II interferon binding |
| Ontology | molecular_function |
| Synonym | IFN-gamma binding, IFNG binding, interferon-gamma binding |
| Major function | Binding to interferon-gamma, initiating signaling cascades such as JAK/STAT |
| Related process | Type II interferon-mediated signaling pathway, immune response |
| Related cellular component | Extracellular space, plasma membrane, cytoplasm |
| Related molecular function | Cytokine binding, receptor activity |
What Is GO:0019964?
According to the Gene Ontology, GO:0019964 (type II interferon binding) is defined as the binding to type II interferon, also known as interferon-gamma. This molecular function encompasses the selective interaction between a protein and IFN-gamma, a cytokine that plays a central role in immune regulation. Synonyms include IFN-gamma binding, IFNG binding, and interferon-gamma binding. The term is used to annotate gene products that physically interact with IFN-gamma, thereby mediating its biological effects.
Why Is type II interferon binding Important in Cell Biology?
Type II interferon binding is crucial because it governs the cellular response to IFN-gamma, a cytokine that orchestrates innate and adaptive immunity. Dysregulation of this binding can lead to impaired host defense, chronic inflammation, or autoimmune pathology. Understanding the molecular details of IFN-gamma binding enables the development of therapeutics that modulate immune responses, as evidenced by studies on viral evasion and inflammatory diseases [1,5,8].
• Mediates the first step in IFN-gamma signaling, essential for immune surveillance.
• Viral proteins can modulate type II interferon binding to enhance T cell adhesion and virus spread.
• Activation of cGAS-STING-IRF3 axis by type II interferon contributes to host defense against pathogens.
• Supersulphides block JAK/STAT signaling, suppressing type II interferon responses in macrophages.
• NPM1 selectively regulates type II interferon-inducible genes, affecting gene expression programs.
• Antigen-specific B cell depletion in pemphigus vulgaris highlights therapeutic targeting of IFN-gamma-related pathways.
• IRE1α-XBP1 controls T cell function in ovarian cancer, linking IFN-gamma signaling to mitochondrial activity.
• N-MYC-interacting protein enhances type II interferon signaling by inhibiting STAT1 sumoylation.
• Clinically validated assays for type II interferon activity aid diagnosis of systemic inflammatory diseases.
Molecular Mechanism of type II interferon binding
IFN-gamma Recognition and Receptor Binding
In simple terms: IFN-gamma binds to its receptor on the cell surface, like a key fitting into a lock.
Type II interferon binding begins with the specific recognition of IFN-gamma by its cognate receptor, IFNGR1 and IFNGR2. This interaction triggers receptor dimerization and activation of associated JAK kinases. Viral modulation of type II interferon can alter this binding to increase T cell adhesion and virus spread. The binding event is highly specific, ensuring that only IFN-gamma, and not type I interferons, activates this pathway.
JAK/STAT Activation and Signal Transduction
In simple terms: After binding, the receptor activates JAK enzymes, which then turn on STAT proteins to carry the signal to the nucleus.
Upon IFN-gamma binding, JAK1 and JAK2 are activated and phosphorylate STAT1. Phosphorylated STAT1 forms dimers that translocate to the nucleus to regulate gene expression. This pathway can be blocked by supersulphides, which suppress type I and type II interferon responses by inhibiting JAK/STAT signaling in macrophages. Additionally, N-MYC-interacting protein enhances type II interferon signaling by inhibiting STAT1 sumoylation, fine-tuning the response.
Regulation by NPM1 and Selective Gene Induction
In simple terms: NPM1 helps control which genes are turned on by IFN-gamma, acting like a volume knob for specific genes.
NPM1/nucleophosmin selectively regulates type II interferon-inducible genes, modulating the transcriptional output downstream of IFN-gamma binding. This selective regulation ensures that appropriate genes are activated for specific cellular contexts, such as immune defense or inflammation.
Crosstalk with cGAS-STING-IRF3 Axis
In simple terms: IFN-gamma binding can also activate other immune sensors, like cGAS-STING, to boost host defense.
Activation of the cGAS-STING-IRF3 axis by type I and II interferons contributes to host defense, indicating that type II interferon binding can synergize with cytosolic DNA sensing pathways. This crosstalk amplifies immune responses against pathogens.
Mitochondrial Regulation and T Cell Function
In simple terms: IFN-gamma signaling affects how T cells use energy, influencing their function in cancer.
IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity, linking type II interferon binding to metabolic reprogramming in T cells. This suggests that IFN-gamma binding not only triggers immediate signaling but also shapes long-term cellular metabolism.
Key Genes Involved in GO:0019964 type II interferon binding
The following genes and proteins are directly involved in type II interferon binding and its downstream signaling, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IFNGR1 | Alpha chain of IFN-gamma receptor, binds IFN-gamma | Mediates initial binding and receptor assembly |
| IFNGR2 | Beta chain of IFN-gamma receptor, signal transduction | Required for JAK/STAT activation |
| JAK1 | Janus kinase 1, phosphorylates STAT1 | Key kinase in IFN-gamma signaling |
| JAK2 | Janus kinase 2, phosphorylates STAT1 | Essential for signal transduction |
| STAT1 | Signal transducer and activator of transcription 1 | Central mediator of IFN-gamma-induced gene expression |
| NPM1 | Nucleophosmin, regulates type II interferon-inducible genes | Selective modulation of gene expression |
| NMI | N-MYC-interacting protein, enhances IFN-gamma signaling | Inhibits STAT1 sumoylation |
| cGAS | Cyclic GMP-AMP synthase, DNA sensor | Crosstalk with IFN-gamma signaling |
| STING | Stimulator of interferon genes | Activates IRF3 downstream of cGAS |
| IRF3 | Interferon regulatory factor 3 | Transcription factor for interferon-stimulated genes |
| IRE1α | Inositol-requiring enzyme 1 alpha | Regulates T cell mitochondrial activity |
| XBP1 | X-box binding protein 1 | Transcription factor downstream of IRE1α |
| IFNG | Interferon gamma | Ligand for type II interferon binding |
| IFNGR1/2 complex | Functional receptor complex | Target for viral modulation |
| SOCS1 | Suppressor of cytokine signaling 1 | Negative regulator of JAK/STAT |
| PIAS1 | Protein inhibitor of activated STAT1 | Regulates STAT1 sumoylation |
| SUMO1 | Small ubiquitin-like modifier 1 | Modifies STAT1, affecting signaling |
How Is type II interferon binding Regulated?
Type II interferon binding and its downstream signaling are tightly regulated at multiple levels. Supersulphides can suppress type I and type II interferon responses by blocking JAK/STAT signaling in macrophages. N-MYC-interacting protein enhances type II interferon signaling by inhibiting STAT1 sumoylation, providing a positive regulatory mechanism. Additionally, NPM1 selectively regulates type II interferon-inducible genes, ensuring appropriate gene expression. Viral proteins can modulate type II interferon binding to increase T cell adhesion and virus spread, illustrating pathogen-driven regulation. These regulatory mechanisms highlight potential therapeutic targets for modulating IFN-gamma responses.
type II interferon binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFNGR1 | Viral infections, immune evasion | Knockout mice or cell lines |
| STAT1 | Autoimmune diseases, cancer | Point mutation knock-in |
| NPM1 | Leukemia, gene regulation | Overexpression and knockout |
| IRE1α | Ovarian cancer, T cell metabolism | Conditional knockout |
| cGAS | Inflammatory diseases, host defense | Knockout and knock-in |
Autoimmune and Inflammatory Diseases
Dysregulated type II interferon binding is implicated in autoimmune conditions such as pemphigus vulgaris, where antigen-specific B cell depletion has been explored as a precision therapy. Clinically validated assays for type I and type II interferon activity aid in diagnosing systemic inflammatory diseases, underscoring the clinical relevance of IFN-gamma binding.
Cancer Immunology
In ovarian cancer, IRE1α-XBP1 controls T cell function by regulating mitochondrial activity, linking type II interferon binding to anti-tumor immunity. Understanding how IFN-gamma binding influences T cell metabolism could inform immunotherapeutic strategies.
Viral Pathogenesis
Viral modulation of type II interferon increases T cell adhesion and virus spread, demonstrating how pathogens exploit IFN-gamma binding to enhance infectivity. This highlights the need for antiviral therapies that target these interactions.
Host Defense and Innate Immunity
Activation of the cGAS-STING-IRF3 axis by type I and II interferons contributes to host defense, indicating that type II interferon binding is integral to innate immune responses against pathogens.
From type II interferon binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IFNGR1 binding to IFN-gamma require specific residues? | Point mutation knock-in |
| What is the effect of IFNGR1 knockout on viral spread? | Knockout cell line or mouse |
| How does STAT1 sumoylation affect IFN-gamma signaling? | Knock-in of SUMO-deficient STAT1 |
| Can NPM1 overexpression alter IFN-inducible genes? | Overexpression cell model |
| What is the role of IRE1α in T cell mitochondrial activity? | Conditional knockout |
| How does cGAS-STING crosstalk with IFN-gamma? | Double knockout and rescue |
How to Study the type II interferon binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | IFN-gamma-receptor interaction |
| RNA-seq | Gene expression changes | Identifying IFN-stimulated genes |
| Phosphoproteomics | Phosphorylation events | JAK/STAT activation |
| Immunoprecipitation | Protein-protein interactions | Detecting STAT1 sumoylation |
| Flow cytometry | Cell surface markers and adhesion | T cell adhesion assays |
| CRISPR screening | Gene essentiality in IFN-gamma response | Identifying novel regulators |
| Bioinformatics pathway analysis | Enrichment of signaling pathways | Interpreting omics data |
Binding Assays
Surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) can measure the binding affinity between IFN-gamma and its receptor or other binding partners. These methods provide quantitative data on the molecular function GO:0019964.
Transcriptomics and Gene Expression Profiling
RNA-seq can identify genes differentially expressed upon IFN-gamma binding, revealing downstream targets regulated by NPM1 or STAT1 [4,7]. This approach helps map the transcriptional landscape of type II interferon responses.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can detect phosphorylation events in JAK/STAT signaling after IFN-gamma binding, as well as sumoylation of STAT1. This provides a systems-level view of signaling dynamics.
Imaging and Flow Cytometry
Fluorescence microscopy and flow cytometry can visualize receptor internalization, STAT1 nuclear translocation, and T cell adhesion changes induced by IFN-gamma binding. These techniques are useful for studying cellular responses in real time.
How CRISPR Can Be Used to Study GO:0019964 type II interferon binding
Knockout
CRISPR knockout of IFNGR1, JAK1, or STAT1 can abolish type II interferon binding and downstream signaling, providing a clean background to study the specific contributions of these genes [1,3]. Knockout cell lines are valuable for validating drug targets and understanding resistance mechanisms.
Point Mutation
Introducing point mutations in the IFN-gamma binding interface of IFNGR1 can dissect the structural requirements for binding and receptor activation. For example, mutations that disrupt STAT1 sumoylation sites can reveal regulatory mechanisms.
Knock-in
Knock-in of tagged IFNGR1 or STAT1 allows for live-cell imaging and proteomic analysis of the binding complex. This approach can also be used to express disease-associated variants to study their impact on IFN-gamma signaling.
Overexpression
Overexpression of NPM1 or NMI can enhance or modulate type II interferon responses, enabling researchers to study gain-of-function effects on gene expression and cellular phenotypes [4,7]. Overexpression models are useful for identifying downstream targets and feedback loops.
How EDITGENE Supports type II interferon binding Research
Researchers studying type II interferon binding-related genes often need to determine whether a candidate gene is causally involved in IFN-gamma signaling or merely correlated with the response. EDITGENE provides a comprehensive suite of CRISPR-based services to enable precise genetic manipulation and functional validation.
Contact EDITGENE today to design your custom CRISPR model for type II interferon binding research.
Frequently Asked Questions About type II interferon binding
What is type II interferon binding?
Type II interferon binding (GO:0019964) is a molecular function defined as the binding to type II interferon, also known as interferon-gamma, a cytokine critical for immune responses.
What genes are involved in type II interferon binding?
Key genes include IFNGR1, IFNGR2, JAK1, JAK2, STAT1, NPM1, NMI, and others that mediate or regulate the binding and downstream signaling [1,3,4,7].
How does type II interferon binding activate JAK/STAT signaling?
Upon IFN-gamma binding, the receptor dimerizes and activates JAK kinases, which phosphorylate STAT1, leading to its nuclear translocation and gene regulation [3,7].
What diseases are associated with type II interferon binding?
Dysregulation is linked to autoimmune diseases like pemphigus vulgaris, inflammatory conditions, viral infections, and cancer [1,5,6,8].
Can viruses modulate type II interferon binding?
Yes, viral proteins can modulate type II interferon binding to increase T cell adhesion and virus spread, as shown in recent studies.
What methods are used to study type II interferon binding?
Common methods include surface plasmon resonance, RNA-seq, phosphoproteomics, flow cytometry, and CRISPR screening [1,4,7].
What is the role of NPM1 in type II interferon binding?
NPM1 selectively regulates type II interferon-inducible genes, modulating the transcriptional output downstream of IFN-gamma binding.
How do supersulphides affect type II interferon responses?
Supersulphides suppress type I and type II interferon responses by blocking JAK/STAT signaling in macrophages.
What is the cGAS-STING-IRF3 axis and its link to type II interferon?
The cGAS-STING-IRF3 axis is a cytosolic DNA sensing pathway that can be activated by type I and II interferons, contributing to host defense.
How can CRISPR be used to study type II interferon binding?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes involved in IFN-gamma binding to study their function and signaling [1,3,7].
Conclusion
Type II interferon binding (GO:0019964) is a fundamental molecular function that initiates IFN-gamma signaling, with broad implications for immunity, disease, and therapeutic development. Understanding its mechanisms, regulation, and crosstalk with other pathways is essential for advancing research in immunology and medicine. EDITGENE's CRISPR services provide powerful tools to dissect these processes and accelerate discovery.
References
- 1. Jacobsen C et al.. 2024. Viral modulation of type II interferon increases T cell adhesion and virus spread.. Nat Commun 15(1):5318 PMID: 38909022
- 2. Tong Z et al.. 2024. Activation of the cGAS-STING-IRF3 Axis by Type I and II Interferons Contributes to Host Defense.. Adv Sci (Weinh) 11(35):e2308890 PMID: 39004913
- 3. Li X et al.. 2024. Supersulphides suppress type-I and type-II interferon responses by blocking JAK/STAT signalling in macrophages.. Int Immunol 36(12):641-652 PMID: 38899915
- 4. Abe M et al.. 2018. Selective regulation of type II interferon-inducible genes by NPM1/nucleophosmin.. FEBS Lett 592(2):244-255 PMID: 29251779
- 5. Lee J et al.. 2020. Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris.. J Clin Invest 130(12):6317-6324 PMID: 32817591
- 6. Song M et al.. 2018. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.. Nature 562(7727):423-428 PMID: 30305738
- 7. Feng L et al.. 2023. N-MYC-interacting protein enhances type II interferon signaling by inhibiting STAT1 sumoylation.. FASEB J 37(12):e23281 PMID: 37933920
- 8. Lam MT et al.. 2026. Clinically validated assay for rapid determination of type I and type II interferon activity in systemic inflammatory diseases.. J Allergy Clin Immunol 157(6):1411-1422.e12 PMID: 41638262
